Press Releases
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Excerpt from the Press Release: Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced…
Read More
Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition Excerpt from the Press Release: WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous…
Read More
OICR announces support for five projects through its Cancer Therapeutics Innovation Pipeline (CTIP) Excerpt from the Press Release: Ontario research teams investigating new ways to treat cancer are taking the crucial next steps to bring their discoveries to patients thanks to support from the Ontario Institute for Cancer Research (OICR). OICR announced it is funding…
Read More
Excerpt from the Press Release: PALO ALTO, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in…
Read More
Excerpt from the Press Release: SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) — Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed patient enrollment ahead of schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation…
Read More
Excerpt from the Press Release: BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful safety review of the 10 mg dry powder dose safety cohort from the…
Read More
Integrated Biosciences’ new platform has potential to fuel advances in senolytic anti-aging compounds and longevity research AI-driven platform built on work pioneered at MIT identifies three candidates with comparable efficacy and superior medicinal chemistry relative to current investigational compounds Treatment of aged mice reduced number of senescent ‘zombie’ cells and lowered expression of senescence-associated genes…
Read More
Excerpt from the Press Release: SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States. MEK…
Read More
– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date – – Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date – – Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the…
Read More
Excerpt from the Press Release: NATICK, Mass. and QUINCY, Mass., April 26, 2023 /PRNewswire/ — Avenge Bio, Inc. (“Avenge”), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase…
Read More